Teleflex wins 2018 Medical Design Excellence Award for Arrow AC3 Optimus IntraAortic

first_imgReviewed by Alina Shrourou, B.Sc. (Editor)Oct 29 2018Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, is proud to announce the Arrow AC3 Optimus Intra-Aortic Balloon Pump, has been selected as the bronze winner in the cardiovascular device category of the 20th annual Medical Design Excellence Awards competition. The 2018 winning products were announced at the MDEA ceremony held at the Jacob K. Javits Convention Center in New York.The AC3 Optimus IABP helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy. Clinicians may use the pump on patients with the most arrhythmias or with heart rates as high as 200 beats per minute.1, 2 In IABP therapy, a physician inserts an intra-aortic balloon catheter into an artery, and using x-ray or imaging, advances the catheter into the aorta. An IABP console, connected to the catheter, controls the inflation and deflation of the balloon.Related StoriesTen-fold rise in tongue-tie surgery for newborns ‘without any real strong data’Heart disease is still the number 1 killer in Australia, according to latest figuresMathematical model helps quantify metastatic cell behavior”We are proud to receive this honor. As innovators in intra-aortic balloon pumping technology, we have made it our commitment to provide a solution that advances the performance and reliability of automated therapy,” said Stew Strong, President and General Manager of the Interventional Division at Teleflex. “This award is a testament to our passion and dedication to providing purpose-driven innovation to improve the health and quality of people’s lives.”The MDEA competition is the medical technology industry’s premier design competition, committed to searching for the world’s highest caliber medical devices, products, systems or packaging available on the market. Products were judged based on design and engineering innovation, function and user-related innovation, patient benefits, business benefits, and overall benefit to the healthcare system. Source:

Leave a Reply

Your email address will not be published. Required fields are marked *